Pulse Biosciences Files 8-K Report
Ticker: PLSE · Form: 8-K · Filed: Sep 8, 2025 · CIK: 1625101
| Field | Detail |
|---|---|
| Company | Pulse Biosciences, Inc. (PLSE) |
| Form Type | 8-K |
| Filed Date | Sep 8, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
Pulse Biosciences filed an 8-K, mostly procedural stuff, no major news yet.
AI Summary
On September 8, 2025, Pulse Biosciences, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific material events detailed in the provided text. The company, formerly known as Electroblate, Inc., is incorporated in Delaware and headquartered in Hayward, California.
Why It Matters
This 8-K filing indicates Pulse Biosciences, Inc. is fulfilling its reporting obligations with the SEC, though the specific details of "Other Events" are not elaborated in this excerpt.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report with no immediate indication of significant positive or negative developments.
Key Numbers
- 001-37744 — SEC File Number (Identifies the company's filing with the SEC.)
- 46-5696597 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Pulse Biosciences, Inc. (company) — Registrant
- Electroblate, Inc. (company) — Former company name
- September 8, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Hayward, California (location) — Principal executive offices location
FAQ
What specific "Other Events" are being reported by Pulse Biosciences, Inc. in this 8-K filing?
The provided text of the 8-K filing does not specify the details of the "Other Events" beyond listing it as an item information category.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on September 8, 2025.
What is the principal executive office address for Pulse Biosciences, Inc.?
The principal executive offices are located at 601 Brickell Key Drive, Suite 1080, Miami, Florida, 33131.
What were Pulse Biosciences, Inc.'s former company names?
Pulse Biosciences, Inc. was formerly known as Pulse Biosciences, Inc. (after a name change on 20151210) and prior to that, Electroblate, Inc. (after a name change on 20141113).
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Stats: 690 words · 3 min read · ~2 pages · Grade level 12.4 · Accepted 2025-09-08 16:05:54
Key Financial Figures
- $0.001 — nge on Which Registered Common stock , $0.001 par value per share PLSE The Nasdaq
Filing Documents
- plse20250905_8k.htm (8-K) — 27KB
- ex_859478.htm (EX-99.1) — 14KB
- 0001437749-25-028560.txt ( ) — 174KB
- plse-20250908.xsd (EX-101.SCH) — 3KB
- plse-20250908_def.xml (EX-101.DEF) — 11KB
- plse-20250908_lab.xml (EX-101.LAB) — 15KB
- plse-20250908_pre.xml (EX-101.PRE) — 11KB
- plse20250905_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events. On September 8, 2025, Pulse Biosciences, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration had granted approval for the Company's Investigational Device Exemption ("IDE"), allowing the Company to proceed with the initiation of its nsPFA Cardiac Surgery System Study, NANOCLAMP AF, for the treatment of atrial fibrillation ("AF"). This single-arm, prospective study is designed to demonstrate primary effectiveness of the nsPFA Cardiac Surgical System for the treatment of AF in concomitant surgical procedures. Up to twenty sites, including two outside the United States, are planned to enroll up to 136 patients in the study. A copy of the press release related to the matters set forth herein is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Forward Looking Statements
Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding enrollment into the Company's IDE clinical trial of its nsPFA Cardiac Surgical System and whether the study can be completed successfully, and whether the study data will demonstrate the safety and effectiveness of the Company's nsPFA Cardiac Surgical System for the treatment of AF. Forward-looking statements are based on management's current expectations and assumptions and are subject to risks and uncertainties, such as clinical, regulatory and technological risks, that could cause actual results to differ materially from those expressed or implied from such statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release issued by Pulse Biosciences, Inc. dated September 8, 2025 - Pulse Biosciences Announces FDA Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PULSE BIOSCIENCES, INC. Date: September 8, 2025 By: /s/ Paul A. LaViolette Paul LaViolette Chief Executive Officer (Principal Executive Officer)